GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra® (ofatumumab)

GlaxoSmithKline (GSK)GlaxoSmithKline (GSK) and Genmab AS confirmed that the European Commission (EC) has granted a conditional marketing authorisation for Arzerra® (ofatumumab) for the treatment of refractory chronic lymphocytic leukaemia (CLL). Ofatumumab is indicated for the treatment of CLL in patients who are refractory (have not responded) to fludarabine and alemtuzumab. Fludarabine and alemtuzumab are standard therapies currently used to treat CLL.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

Genmab AS is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology visit